How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,298 results for

HIPAA

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Decreased Rectal Meconium Signal on MRI in Fetuses with Open Spinal Dysraphism. (Abstract)

Decreased Rectal Meconium Signal on MRI in Fetuses with Open Spinal Dysraphism. To evaluate rectal meconium signal in fetuses with open spinal dysraphism and correlate findings with postnatal exam.This is a single-institution Institutional Review Board-approved Health Insurance Portability and Accountability Act (HIPAA) compliant retrospective analysis of fetal MRIs of open spinal dysraphism from 2004 to 2016. Fetuses with diagnostic T1-weighted images and postnatal follow-up at our institution

2018 Prenatal diagnosis

182. Barriers to Safety Event Reporting in an Academic Radiology Department: Authority Gradients and Other Human Factors. Full Text available with Trip Pro

Barriers to Safety Event Reporting in an Academic Radiology Department: Authority Gradients and Other Human Factors. Purpose To investigate barriers to reporting safety concerns in an academic radiology department and to evaluate the role of human factors, including authority gradients, as potential barriers to safety concern reporting. Materials and Methods In this institutional review board-approved, HIPAA-compliant retrospective study, an online questionnaire link was emailed four times

2018 Radiology

183. Secure smartphone application-based text messaging in emergency department, a system implementation and review of literature. (Abstract)

inter-hospital communication and patient outcomes.We conducted a systematic literature review in PubMed, MEDLINE using the keywords Health Insurance Portability and Accountability Act (HIPAA) Compliant Group Messaging (HCGM), text paging communication, secure hospital text message, HIPAA text message, and secure hospital communication. The search considered studies published until January 2018. Only English-language studies were included. We reviewed the reference lists of included articles

2018 American Journal of Emergency Medicine

184. Clinical 3D printing: A protected health information (PHI) and compliance perspective. (Abstract)

no provisions in the Health Insurance Portability and Accountability Act (HIPAA) either in its original 1996 form or in more recent updates that address the nature of physical representations of clinical data. We submit that if we define the source data as protected health information (PHI), then the objects 3D printed from that data need to be treated as both (PHI), and if used clinically, part of the clinical record, and propose some basic guidelines for quality and privacy like all documentation until

2018 International journal of medical informatics

185. Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. Full Text available with Trip Pro

(AS). Materials and Methods Through use of the Surveillance, Epidemiology, and End Results-Medicare-linked database from 2002 to 2011 with at least 1 year of consecutive follow-up, a HIPAA-compliant retrospective propensity score-matched study of patients with T1aN0M0 RCC who underwent PN, RN, TA, or AS was performed. Medicare beneficiaries (n = 10 218) with T1aN0M0 RCC as first primary cancer diagnosis were included. Survival and adverse health outcomes were compared across treatment groups. Results Overall

2018 Radiology

186. Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology. Full Text available with Trip Pro

Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology. Purpose To assess the diagnostic performance and interreader agreement of a standardized diagnostic algorithm in determining the histologic type of small (≤4 cm) renal masses (SRMs) with multiparametric magnetic resonance (MR) imaging. Materials and Methods This single-center retrospective HIPAA-compliant institutional review board-approved study included 103

2018 Radiology

187. Electronic Communication in Plastic Surgery: Guiding Principles from the American Society of Plastic Surgeons Health Policy Committee. (Abstract)

of these technologies.A search was performed on PubMed and the Cochrane database; terms included "telemedicine," "text messaging," "HIPAA," "metadata," "video conferencing," "photo sharing," "social media," "Facebook," "Twitter," and "Instagram." Initial screening of all identified articles was performed; the level of evidence, limitations, and recommendations were evaluated and articles were reviewed.A total of 654 articles were identified in the level I screening process; after more comprehensive review, 41

2018 Plastic and reconstructive surgery

188. What Happens after a Diagnosis of High-Risk Breast Lesion at Stereotactic Vacuum-assisted Biopsy? An Observational Study of Postdiagnosis Management and Imaging Adherence. Full Text available with Trip Pro

-approved HIPAA-compliant retrospective study included 208 patients who underwent stereotactic biopsy between January 2012 and December 2014 that revealed a high-risk lesion. Whether the patient underwent surgical excision and/or follow-up mammography was documented. Adherence of these women to a protocol of subsequent mammography within 1 year (9-18 months) or within 2 years (9-30 months) was compared with that of 45 508 women with normal screening mammograms who were imaged during the same time period

2018 Radiology

189. The Incidental Splenic Mass at CT: Does It Need Further Work-up? An Observational Study. Full Text available with Trip Pro

The Incidental Splenic Mass at CT: Does It Need Further Work-up? An Observational Study. Purpose To evaluate whether an incidentally noted splenic mass at abdominal computed tomography (CT) requires further imaging work-up. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective study, a search of a CT database was performed for patients with splenic masses at CT examinations of the abdomen and chest from 2002 to 2008. Patients were divided into three

2018 Radiology

190. Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Men and women ≥ 18 years of age at the time of informed consent. ECOG Performance Status of 0 or 1 within 28 days prior to registration. Histologic or cytologic diagnosis of metastatic breast cancer (unless metastatic disease is definitive

2018 Clinical Trials

191. The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.] ii. Facial acne vulgaris in patients with skin of color (Fitzpatrick Type V & VI Supplement VI) characterized by the following: IGA Score for acne vulgaris 3 IGA Score for PIH 3 iii. Able to understand and comply with the requirements of the study and sign Informed Consent /HIPAA Authorization forms Exclusion Criteria: i

2018 Clinical Trials

192. Lutronic Infini and LaseMD Systems in Combination Treatment

informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Presence of an active systemic or local skin disease that may affect wound healing. History of keloids or poor wound healing. Severe solar elastosis. Excessive subcutaneous fat in the area(s) to be treated. Excessive skin laxity on the area(s) to be treated. Significant scarring in the area(s) to be treated that would interfere with assessing results. Open wounds or lesions in the area(s

2018 Clinical Trials

193. Lutronic LaseMD for Treatment of Benign Pigmented Lesions

and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Presence of an active systemic or local skin disease that may affect wound healing. History of keloids or poor wound healing. Significant scarring in the area(s) to be treated that would interfere with assessing results. Open wounds or lesions in the area(s) to be treated. Inability to understand the protocol or to give informed consent. Microdermabrasion

2018 Clinical Trials

194. Non-invasive Cervical Electrical Stimulation for SCI

-017 First Posted: January 30, 2018 Last Update Posted: January 30, 2018 Last Verified: January 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: A Limited Dataset (LDS), with individual electrophysiological and physiological outcome measures, will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate (...) Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated

2018 Clinical Trials

195. Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: SU2C HRI NPG-001 First Posted: January 30, 2018 Last Update Posted: July 18, 2018 Last Verified: July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA), the Investigator will ensure that the patient consents to the use of data by HonorHealth and its designees

2018 Clinical Trials

196. Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

at least 3 minutes apart during screening; Schirmer tear test with anesthesia <7 mm/5 min in at least one eye during screening; Willingness and and ability to undergo, and return for, all scheduled study-related visits through Follow-up (Appendix 21.1); Willingness and and ability to provide written Informed Consent consistent with privacy language as per national regulations (e.g., HIPAA authorization) and which signature may be obtained from the patient or legally authorized representative prior

2018 Clinical Trials

197. Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

ages 12 to 17 years of age inclusive must have provided IRB approved written assent; this written assent must be accompanied by an IRB approved written informed consent from the Subject's legally acceptable representative (i.e., parent or guardian). In addition, all Subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a HIPAA authorization. Subjects must have a minimum ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20 inflammatory lesions

2018 Clinical Trials

198. Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

in accordance with the HIPAA Privacy Rule (45 C.F.R. § 164.514(b)). Supporting Materials: Study Protocol Statistical Analysis Plan (SAP) Analytic Code Time Frame: The dataset will be available after completion of the study and publication of results. Access Criteria: Third party data requests will be reviewed by a committee, and approved requests will require a DUA. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product

2018 Clinical Trials

199. Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Eligibility Criteria: Written informed consent and HIPAA authorization for release of personal health information. Patients must sign a consent to undergo cell procurement. Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion. Age ≥ 18

2018 Clinical Trials

200. Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

Subjects with child bearing or fathering potential must agree to use adequate contraception during the study and for 3 months after last treatment of investigational drug. Agree to study specific informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information Adequate baseline complete blood count (CBC), renal and hepatic function Parameters described as WBC > 3000 cells/mm3, ANC > 1,000 cells/mm3, hemoglobin > 8.5 g/dL

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>